About Tune Therapeutics
Tune Therapeutics is a company based in Seattle (United States) founded in 2009 by Akira Matsuno, Daniel McHugh, and Christina Trojel-Hansen.. Tune Therapeutics has raised $222.41 million across 2 funding rounds from investors including NEA, Yosemite and Regeneron Ventures. Tune Therapeutics offers products and services including TEMPO Platform. Tune Therapeutics operates in a competitive market with competitors including Insitro, BridgeBio, ATAI, Forge Biologics and Spark Therapeutics, among others.
- Headquarter Seattle, United States
- Founders Akira Matsuno, Daniel McHugh, Christina Trojel-Hansen
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$222.41 M (USD)
in 2 rounds
-
Latest Funding Round
$182.41 M (USD), Series B
Mar 09, 2023
-
Investors
NEA
& 6 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Tune Therapeutics
Tune Therapeutics offers a comprehensive portfolio of products and services, including TEMPO Platform. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Enables control of gene expression for treating diseases without DNA alteration.
Unlock access to complete
Unlock access to complete
Funding Insights of Tune Therapeutics
Tune Therapeutics has successfully raised a total of $222.41M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $182.41 million completed in March 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 2
- Last Round Series B — $182.4M
-
First Round
First Round
(02 Dec 2021)
- Investors Count 7
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar, 2023 | Amount | Series B - Tune Therapeutics | Valuation | New Enterprise Associates | |
| Dec, 2021 | Amount | Series A - Tune Therapeutics | Valuation | New Enterprise Associates , Emerson Collective |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Tune Therapeutics
Tune Therapeutics has secured backing from 7 investors, including venture fund and institutional investors. Prominent investors backing the company include NEA, Yosemite and Regeneron Ventures. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital investments are offered to startups by NEA.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in biopharmaceutical and healthcare firms.
|
Founded Year | Domain | Location | |
|
Tech & Life Sciences focused VC firm investing in early stage companies in the US & Europe
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Tune Therapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Tune Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Tune Therapeutics Comparisons
Competitors of Tune Therapeutics
Tune Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Insitro, BridgeBio, ATAI, Forge Biologics and Spark Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
An AI-enabled platform is developed for infectious disease treatment.
|
|
| domain | founded_year | HQ Location |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| domain | founded_year | HQ Location |
A biopharmaceutical company accelerating innovative mental health treatments.
|
|
| domain | founded_year | HQ Location |
Gene therapies for rare diseases are developed to treat patients.
|
|
| domain | founded_year | HQ Location |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| domain | founded_year | HQ Location |
Provider of cell therapies to treat cancer and hematologic conditions
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Tune Therapeutics
Frequently Asked Questions about Tune Therapeutics
When was Tune Therapeutics founded?
Tune Therapeutics was founded in 2009 and raised its 1st funding round 12 years after it was founded.
Where is Tune Therapeutics located?
Tune Therapeutics is headquartered in Seattle, United States. It is registered at Seattle, Washington, United States.
Is Tune Therapeutics a funded company?
Tune Therapeutics is a funded company, having raised a total of $222.41M across 2 funding rounds to date. The company's 1st funding round was a Series A of $40M, raised on Dec 02, 2021.
What does Tune Therapeutics do?
Tune Therapeutics was founded in 2009 and is based in Seattle, United States. The company operates in the biotechnology sector, focusing on cell and gene therapies for complex diseases. An epigenome editing and gene regulation platform is utilized to create therapeutics that avoid alterations to the DNA sequence. Operations emphasize innovative approaches to disease treatment through epigenetic modifications.
Who are the top competitors of Tune Therapeutics?
Tune Therapeutics's top competitors include Spark Therapeutics, BridgeBio and Forge Biologics.
What products or services does Tune Therapeutics offer?
Tune Therapeutics offers TEMPO Platform.
Who are Tune Therapeutics's investors?
Tune Therapeutics has 7 investors. Key investors include NEA, Yosemite, Regeneron Ventures, Hevolution Foundation, and Hatteras Venture Partners.